Arabic Arabic English English French French German German
dark

First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study

Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, announced that the first patient has been treated in the KIDCARES10 (KIg10 in peDiatric subjects: effiCacy, sAfety and phaRmacokinEticS of a 10% IG) clinical trial. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

Next Post

MOH: Precautionary Measures to Be Followed by Pilgrims

Related Posts
Total
0
Share